EE05432B1 - Prroloprimidiinid kui valgukinaasi inhibiitorid - Google Patents
Prroloprimidiinid kui valgukinaasi inhibiitoridInfo
- Publication number
- EE05432B1 EE05432B1 EEP200400003A EEP200400003A EE05432B1 EE 05432 B1 EE05432 B1 EE 05432B1 EE P200400003 A EEP200400003 A EE P200400003A EE P200400003 A EEP200400003 A EE P200400003A EE 05432 B1 EE05432 B1 EE 05432B1
- Authority
- EE
- Estonia
- Prior art keywords
- rrolop
- rimidines
- protein kinase
- kinase inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0115393.1A GB0115393D0 (en) | 2001-06-23 | 2001-06-23 | Chemical compounds |
US30167801P | 2001-06-28 | 2001-06-28 | |
PCT/GB2002/002835 WO2003000695A1 (fr) | 2001-06-23 | 2002-06-21 | Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200400003A EE200400003A (et) | 2004-02-16 |
EE05432B1 true EE05432B1 (et) | 2011-06-15 |
Family
ID=9917225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200400003A EE05432B1 (et) | 2001-06-23 | 2002-06-21 | Prroloprimidiinid kui valgukinaasi inhibiitorid |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1404676A1 (fr) |
JP (1) | JP4344607B2 (fr) |
CN (1) | CN1294135C (fr) |
AU (1) | AU2002314325B8 (fr) |
BR (1) | BR0210652A (fr) |
CA (1) | CA2451932C (fr) |
CZ (1) | CZ20033443A3 (fr) |
EA (1) | EA007415B1 (fr) |
EC (1) | ECSP034922A (fr) |
EE (1) | EE05432B1 (fr) |
GB (1) | GB0115393D0 (fr) |
HU (1) | HUP0400300A3 (fr) |
ME (1) | MEP19308A (fr) |
NZ (1) | NZ529766A (fr) |
OA (1) | OA12632A (fr) |
PL (1) | PL374096A1 (fr) |
RS (1) | RS51698B (fr) |
SK (1) | SK15882003A3 (fr) |
TN (1) | TNSN03144A1 (fr) |
TR (1) | TR200302242T2 (fr) |
UA (1) | UA76760C2 (fr) |
WO (1) | WO2003000695A1 (fr) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
US7517886B2 (en) | 2002-07-29 | 2009-04-14 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
EP1687309A1 (fr) | 2003-11-17 | 2006-08-09 | Pfizer Products Inc. | Composés de pyrrolopyrimidine utiles dans le traitement du cancer |
BRPI0416909A (pt) * | 2003-11-25 | 2007-01-16 | Pfizer Prod Inc | método de tratamento de aterosclerose |
US20050250829A1 (en) * | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Kinase inhibitors |
FR2876103B1 (fr) * | 2004-10-01 | 2008-02-22 | Aventis Pharma Sa | Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
FR2878849B1 (fr) | 2004-12-06 | 2008-09-12 | Aventis Pharma Sa | Indoles substitues, compositions les contenant, procede de fabrication et utilisation |
CA2607901C (fr) | 2005-06-13 | 2016-08-16 | Rigel Pharmaceuticals, Inc. | Methodes et compositions pour le traitement de maladies osseuses degeneratives comprenant un compose inhibiteur syk 2,4-pyrimidinediamine |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
MY162590A (en) | 2005-12-13 | 2017-06-30 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors |
JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
EP3495369B1 (fr) | 2007-06-13 | 2021-10-27 | Incyte Holdings Corporation | Utilisation des sels de l'inhibiteur de janus kinase (r)-3-(4-(7h-pyrrolo [2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
NZ586642A (en) | 2008-01-11 | 2012-04-27 | Natco Pharma Ltd | Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents |
PE20140407A1 (es) | 2008-06-10 | 2014-04-25 | Abbott Lab | Nuevos compuestos triciclicos |
MX2011012262A (es) | 2009-05-22 | 2012-01-25 | Incyte Corp | 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il] octano-o heptano-nitrilo como inhibidores de cinasas janus (jak). |
EA025520B1 (ru) | 2009-05-22 | 2017-01-30 | Инсайт Холдингс Корпорейшн | N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ |
WO2011018894A1 (fr) * | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Dérivés de pyrrolopyrimidine comme modulateurs des canaux potassium |
TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9029359B2 (en) | 2009-09-04 | 2015-05-12 | Biogen Idec Ma, Inc. | Heteroaryl Btk inhibitors |
TW201802091A (zh) * | 2009-12-01 | 2018-01-16 | 艾伯維有限公司 | 新穎三環化合物 |
SI3354652T1 (sl) | 2010-03-10 | 2020-08-31 | Incyte Holdings Corporation | Derivati piperidin-4-il azetidina kot inhibitorji JAK1 |
SG10201910912TA (en) | 2010-05-21 | 2020-01-30 | Incyte Corp | Topical Formulation for a JAK Inhibitor |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
BR112013012502A2 (pt) | 2010-11-19 | 2019-03-06 | Incyte Corporation | pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak |
CN102093364B (zh) * | 2011-01-07 | 2015-01-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
CN103476776B (zh) * | 2011-01-07 | 2016-09-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
JP6182593B2 (ja) | 2012-04-20 | 2017-08-16 | アドヴィーナス セラピューティクス リミテッド | 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途 |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
DK2877467T3 (en) | 2012-07-26 | 2017-02-13 | Glaxo Group Ltd | 2- (AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS |
JP6318156B2 (ja) * | 2012-09-06 | 2018-04-25 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼをモジュレートするための化合物および方法、ならびにその指標 |
SG11201503695XA (en) | 2012-11-15 | 2015-06-29 | Incyte Corp | Sustained-release dosage forms of ruxolitinib |
EA030705B1 (ru) | 2013-03-06 | 2018-09-28 | Инсайт Холдингс Корпорейшн | Способы и промежуточные соединения при получении ингибитора jak |
AU2014244263A1 (en) | 2013-03-13 | 2015-08-13 | Abbvie Inc. | CDK9 kinase inhibitors |
BR112015021549A2 (pt) | 2013-03-13 | 2017-07-18 | Abbvie Inc | inibidores de piridina cinase cdk9 |
WO2014151444A1 (fr) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Inhibiteurs de pyrrolo[2,3-b]pyridine cdk9 kinase |
AU2014231567A1 (en) | 2013-03-14 | 2015-10-01 | Abbvie Inc. | Pyrrolo[2,3-b]pyridine CDK9 kinase inhibitors |
JP2016512560A (ja) * | 2013-03-14 | 2016-04-28 | アッヴィ・インコーポレイテッド | ピロロピリミジン系cdk9キナーゼ阻害薬 |
ES2792549T3 (es) | 2013-08-07 | 2020-11-11 | Incyte Corp | Formas de dosificación de liberación sostenida para un inhibidor de JAK1 |
CN104804001B9 (zh) * | 2014-01-24 | 2022-02-08 | 江苏柯菲平医药股份有限公司 | 4-取代吡咯并[2,3-d]嘧啶化合物及其用途 |
WO2015184305A1 (fr) | 2014-05-30 | 2015-12-03 | Incyte Corporation | Traitement de la leucémie neutrophile chronique (cnl) et de la leucémie myéloïde chronique atypique (acml) par des inhibiteurs de jak1 |
SG10201913986YA (en) | 2015-10-16 | 2020-03-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11564922B2 (en) | 2017-03-09 | 2023-01-31 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
WO2018165581A1 (fr) | 2017-03-09 | 2018-09-13 | Abbvie Inc. | Procédés de traitement de la maladie de crohn et de la rectocolite hémorragique |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
PL3746429T3 (pl) | 2018-01-30 | 2022-06-20 | Incyte Corporation | Procesy do otrzymywania (1-(3-fluoro-2-(trifluorometylo)izonikotynoilo)piperydyn-4-onu) |
WO2019191684A1 (fr) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak |
EP3860998B1 (fr) | 2018-10-05 | 2023-12-27 | Annapurna Bio Inc. | Composés et compositions destinés au traitement d'états pathologiques associés à une activité du récepteur de l'apj |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1441497A (en) * | 1996-01-23 | 1997-08-20 | Novartis Ag | Pyrrolopyrimidines and processes for their preparation |
BR9713552A (pt) * | 1996-11-27 | 2000-01-25 | Pfizer | Derivados de pirimidina bicìclicos condensados |
ID26698A (id) * | 1998-06-19 | 2001-02-01 | Pfizer Prod Inc | SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA |
PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
CZ2001959A3 (cs) * | 1998-09-18 | 2001-12-12 | Basf Aktiengesellschaft | 4-Aminopyrrolopyrimidiny jako inhibitory kinasy |
DK1235830T3 (da) * | 1999-12-10 | 2004-03-29 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer |
-
2001
- 2001-06-23 GB GBGB0115393.1A patent/GB0115393D0/en not_active Ceased
-
2002
- 2002-06-21 JP JP2003507098A patent/JP4344607B2/ja not_active Expired - Fee Related
- 2002-06-21 NZ NZ529766A patent/NZ529766A/en not_active IP Right Cessation
- 2002-06-21 TR TR2003/02242T patent/TR200302242T2/xx unknown
- 2002-06-21 PL PL02374096A patent/PL374096A1/xx not_active Application Discontinuation
- 2002-06-21 EA EA200400073A patent/EA007415B1/ru not_active IP Right Cessation
- 2002-06-21 UA UA2004010502A patent/UA76760C2/uk unknown
- 2002-06-21 BR BR0210652-3A patent/BR0210652A/pt not_active Application Discontinuation
- 2002-06-21 TN TNPCT/GB2002/002835A patent/TNSN03144A1/en unknown
- 2002-06-21 EP EP02740895A patent/EP1404676A1/fr not_active Withdrawn
- 2002-06-21 OA OA1200300335A patent/OA12632A/en unknown
- 2002-06-21 RS YU99203A patent/RS51698B/en unknown
- 2002-06-21 SK SK1588-2003A patent/SK15882003A3/sk not_active Application Discontinuation
- 2002-06-21 WO PCT/GB2002/002835 patent/WO2003000695A1/fr active Application Filing
- 2002-06-21 CA CA002451932A patent/CA2451932C/fr not_active Expired - Fee Related
- 2002-06-21 AU AU2002314325A patent/AU2002314325B8/en not_active Ceased
- 2002-06-21 HU HU0400300A patent/HUP0400300A3/hu unknown
- 2002-06-21 ME MEP-193/08A patent/MEP19308A/xx unknown
- 2002-06-21 CN CNB028119320A patent/CN1294135C/zh not_active Expired - Fee Related
- 2002-06-21 EE EEP200400003A patent/EE05432B1/xx not_active IP Right Cessation
- 2002-06-21 CZ CZ20033443A patent/CZ20033443A3/cs unknown
-
2003
- 2003-12-23 EC EC2003004922A patent/ECSP034922A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN1518552A (zh) | 2004-08-04 |
ECSP034922A (es) | 2004-04-28 |
JP2005508300A (ja) | 2005-03-31 |
WO2003000695A1 (fr) | 2003-01-03 |
RS99203A (en) | 2006-12-15 |
TR200302242T2 (tr) | 2004-12-21 |
EA007415B1 (ru) | 2006-10-27 |
NZ529766A (en) | 2008-11-28 |
MEP19308A (en) | 2010-06-10 |
JP4344607B2 (ja) | 2009-10-14 |
CN1294135C (zh) | 2007-01-10 |
SK15882003A3 (sk) | 2004-07-07 |
HUP0400300A3 (en) | 2010-12-28 |
HUP0400300A2 (en) | 2007-08-28 |
AU2002314325B8 (en) | 2009-01-29 |
AU2002314325B2 (en) | 2009-01-08 |
RS51698B (en) | 2011-10-31 |
EE200400003A (et) | 2004-02-16 |
EP1404676A1 (fr) | 2004-04-07 |
CA2451932A1 (fr) | 2003-01-03 |
CA2451932C (fr) | 2009-12-29 |
BR0210652A (pt) | 2004-08-10 |
EA200400073A1 (ru) | 2004-08-26 |
PL374096A1 (en) | 2005-09-19 |
GB0115393D0 (en) | 2001-08-15 |
UA76760C2 (uk) | 2006-09-15 |
TNSN03144A1 (en) | 2005-12-23 |
CZ20033443A3 (en) | 2004-03-17 |
WO2003000695A8 (fr) | 2004-03-11 |
OA12632A (en) | 2006-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE05432B1 (et) | Prroloprimidiinid kui valgukinaasi inhibiitorid | |
NO20041887L (no) | Benzomidazoler anvendelige som proteinkinase-inhibitorer | |
DE60128709D1 (de) | Triazol-verbindungen als protein-kinase-inhibitoren | |
DE60129794D1 (de) | Pyrrol substituierte indolin-2-on protein kinase inhibitoren | |
EE200200140A (et) | Pteridinoonid kui kinaasi inhibiitorid | |
IS6968A (is) | Nýir týrósínkínasa tálmar | |
EE200300385A (et) | 3-(4-amidopürrool-2-üülmetülideen)-2-indolinooni derivaadid kui proteiini kinaasi inhibiitorid | |
DE60120219D1 (de) | Pyrazolverbindungen als protein-kinase-inhibitoren | |
ATE505471T1 (de) | Azaindol-kinaseinhibitoren | |
ID30460A (id) | Inhibitor-inhibitor protein siklik tirosin kinase | |
DK1370553T3 (da) | Rho-kinase-inhibitorer | |
DK1370552T3 (da) | Rho-kinase-inhibitorer | |
EE200300384A (et) | Kinasoliinid kui MMP-13 inhibiitorid | |
NO20035728L (no) | Pyrrolopyrimidiner som proteinkinaseinhibitorer | |
DE60101323D1 (de) | Tricyclische proteinkinasehemmer | |
IL151779A0 (en) | Protein tyrosine kinase inhibitors | |
IL145329A0 (en) | Protein tyrosine kinase inhibitors | |
DK1317448T4 (da) | Pyrazolforbindelser anvendelige som proteinkinaseinhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapsed by not paying the annual fees |
Effective date: 20120621 |